FDA Approves Second Brain Amyloid Imaging Tracer

FDA Approves Second Brain Amyloid Imaging Tracer

Medscape NeurologyHeadlines

The FDA announced approval today for flutemetamol (Vizamyl, GE Healthcare), a second amyloid PET tracer for evaluation of AD and dementia.
FDA Approvals

Original Article: http://www.medscape.com/viewarticle/813222?src=rss

Julio Pereira, MD

Linkedin:http://www.linkedin.com/in/juliommais 

Site: www.neurocirurgiabr.com